# Boehringer Ingelheim's zongertinib is approved as a first-line treatment for a rare form of non-small cell lung cancer.

*biotech · news · 2026-02-26 · Reuters*

## Key points

- The FDA approved Boehringer Ingelheim's zongertinib as a first-line NSCLC treatment targeting rare mutations.
- Zongertinib's first-line approval could double Boehringer's addressable lung cancer market.
- The FDA cleared Hernexeos under the National Priority Voucher Program, processing the application in 44 days.
- In trials, zongertinib shrank tumors in 76% of untreated patients versus 30%-45% for current therapies.

**Companies:** Boehringer Ingelheim
**Countries:** USA, India, UK

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-gives-full-approval-boehringers-lung-cancer-treatment-2026-02-26/)

---

Canonical: https://newsio.io/n/57427b77-3b90-40bb-be3d-b86d3a1e5c9d/boehringer-ingelheims-zongertinib-is-approved-as-a-first-line-treatment-for-a-ra
Summarized by Newsio from Reuters. https://newsio.io/how-it-works